Arthneeti

Sudarshan Pharma Industries Q1 FY27 Share Price & Earnings Call Analysis

₹32.25-8.28% today
Market cap
₹821 Cr
P/E
28.26
ROE
16.26%
PEG
0.60
Price to sales
1.05
Debt to equity
2.01
52W high / low
₹42.3 / ₹19.2
Sales growth (5Y)
29.46%
EBITDA margin
8.66%
Net profit margin
3.32%
Promoter holding
57.81%
Sales (last year)
₹780 Cr

Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Sudarshan Pharma rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Chemicals & Petrochemicals companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 0–2%₹234 Cr3.0
240%+Flat₹3,888 Cr48.5
340%+Flat₹3,514 Cr4.3
440%+Flat₹180 Cr11.9
540%+Flat₹138 Cr15.1
620–40%Up 2%+₹1.70L Cr85.4

Sign up free to see every company in the sector ranking and track Sudarshan Pharma.

Pro shows every company guiding 40%+ revenue growth →Full Chemicals & Petrochemicals ranking

Financials of Sudarshan Pharma

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Sudarshan Pharma

Quarterly Results

Quarter-by-quarter operating performance

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +99129116162145169168221
Expenses +97116108146134160157201
Operating Profit2138161191120
OPM %2%10%7%10%8%5%6%9%
Other Income +1-11-11224
Interest44446668
Depreciation11111111
Profit before tax-2841054516
Tax %-22%25%25%25%27%9%20%27%
Net Profit +-163744411
EPS in Rs-0.050.240.120.310.170.170.180.45

Financials of Sudarshan Pharma

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +148193357461464505703
Expenses +143186346446441465652
Operating Profit571115234051
OPM %3%4%3%3%5%8%7%
Other Income +00013-09
Interest333591626
Depreciation0111124
Profit before tax2479152231
Tax %26%25%26%26%25%26%23%
Net Profit +1357111623
EPS in Rs0.130.280.540.290.480.660.97
Dividend Payout %0%0%0%10%0%0%0%

Financials of Sudarshan Pharma

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital10101024242424
Reserves1013207788107131
Borrowings +21303134105171285
Other Liabilities +1847779767100202
Total Liabilities5899138232283402642
Fixed Assets +666202624104
CWIP0010263
Investments0001214300
Other Assets +5393131200242342534
Total Assets5899138232283402642

Financials of Sudarshan Pharma

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +13-4-29835-2
Cash from Investing Activity +-3-1-1-26-7-20-78
Cash from Financing Activity +-0-1466-12-1479
Net Cash Flow-2-0-111-120-1
Free Cash Flow-41-5-43430-51
CFO/OP20%50%-19%-179%43%96%7%

Financials of Sudarshan Pharma

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days66114756496116121
Inventory Days4649516374117129
Days Payable409180784976111
Cash Conversion Cycle72724650122156139
Working Capital Days35292754595317
ROCE %15%19%15%14%16%15%
36out of 100

Momentum score · price trend

36 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+30.1%78%
Last 6 months+13.5%71%
Last 3 months−2.3%64%

The price is 28% below its all-time high of ₹48.8 (10 Jan 2025). Stocks more than 20% below their peak have their score halved, so 72 became 36.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Sudarshan Pharma: 0.4 × 78 + 0.4 × 71 + 0.2 × 64 = 72, halved to 36 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Sudarshan Pharma's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • J.G.Chemicals (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹3,610 million, up 63.9% YoY (₹2,203 million in Q2 FY26) (Page 23) . Key investor presentation takeaways from J.G.Chemicals Ltd

  • Lords Chloro (Q2 FY27)

    115.40 Crore, up 17.34% YoY from Rs. Key investor presentation takeaways from Lords Chloro Alkali Ltd's Q2 FY27 investor presentation — and how it ranks against

  • Camlin Fine (Q2 FY27)

    Q2 FY27 revenue: Rs 4,915 mn, up 9.15% YoY from Rs 4,503 mn in Q2 FY26 (Page 6, 9) . Key investor presentation takeaways from Camlin Fine Sciences Ltd's Q2 FY27

  • Gujarat Fluoroch (Q2 FY27)

    Consolidated Q2FY27 revenue: ₹1,760 crore, up 45% YoY (Q2FY26: ₹1,210 crore). Key investor presentation takeaways from Gujarat Fluorochemicals Ltd's Q2 FY27 inv

Compare:vs Solar Industriesvs Pidilite Industriesvs SRF